Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors.

Journal of medicinal chemistry·2026
Same author

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

Blood·2026
Same author

Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains.

Molecular systems biology·2026
Same author

AURORA A interacts with DICER and SETD2 to promote S-phase progression.

EMBO reports·2026
Same author

Structure-Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile.

ChemMedChem·2026
Same author

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Sep 17, 2025

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.3K

Covalent Targeting Leads to the Development of a LIMK1 Isoform-Selective Inhibitor.

Sebastian Mandel1,2, Thomas Hanke1,2, Niall Prendiville3

  • 1Institute for Pharmaceutical Chemistry, Johann Wolfgang Goethe-University, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany.

Journal of Medicinal Chemistry
|July 2, 2025
PubMed
Summary

Researchers developed a selective covalent inhibitor for LIMK1, a protein kinase, by targeting a unique cysteine residue. This chemical probe enables precise studies of LIMK1

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K

Related Experiment Videos

Last Updated: Sep 17, 2025

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
11:23

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein

Published on: June 30, 2019

6.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.4K

Area of Science:

  • Biochemistry
  • Chemical Biology
  • Molecular Pharmacology

Background:

  • Achieving isoform selectivity for protein kinases is critical for drug design and chemical probe development.
  • Covalent targeting of unique cysteine residues offers a strategy to overcome conserved binding site challenges.
  • The LIMK (LIM kinase) family, particularly LIMK1 and LIMK2, plays crucial roles in cellular processes.

Purpose of the Study:

  • To design and characterize a cell-active, isoform-selective covalent inhibitor for LIMK1.
  • To utilize LIMK1-specific cysteine targeting for enhanced selectivity over LIMK2.
  • To provide a versatile chemical tool for investigating LIMK1 signaling pathways.

Main Methods:

  • Utilized a pan-LIMK inhibitor scaffold to develop a LIMK1-selective covalent inhibitor.
  • Targeted the LIMK1-specific cysteine C349 located in the glycine-rich loop.
  • Investigated binding kinetics of noncovalent and covalent LIMK inhibitors.
  • Employed type-I inhibitor characteristics (fast on-rate, small size) in inhibitor design.
  • Validated proteome-wide selectivity using pull-down assays.

Main Results:

  • Developed a cell-active covalent inhibitor that selectively targets LIMK1 over LIMK2.
  • Demonstrated excellent proteome-wide selectivity of the developed inhibitor.
  • Confirmed targeting of the LIMK1-specific cysteine C349.
  • The inhibitor's design incorporated fast on-rate and small size features.

Conclusions:

  • A novel, highly selective covalent LIMK1 inhibitor was successfully developed.
  • This inhibitor serves as a valuable chemical probe for studying LIMK1 isoform-specific functions.
  • The approach of targeting unique cysteines is effective for achieving kinase selectivity.
  • The tool facilitates research into the LIMK signaling pathway.